Ambu A/S (AMBBY)
| Market Cap | 3.45B +1.1% |
| Revenue (ttm) | 983.30M +7.2% |
| Net Income | 97.56M +5.4% |
| EPS | 0.36 +6.1% |
| Shares Out | n/a |
| PE Ratio | 36.40 |
| Forward PE | 26.36 |
| Dividend | 0.06 (0.48%) |
| Ex-Dividend Date | Dec 5, 2025 |
| Volume | 100 |
| Open | 13.00 |
| Previous Close | 13.60 |
| Day's Range | 13.00 - 13.20 |
| 52-Week Range | 8.55 - 14.18 |
| Beta | 1.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also prov... [Read more]
Financial Performance
In fiscal year 2026, Ambu A/S's revenue was 6.47 billion, an increase of 7.19% compared to the previous year's 6.04 billion. Earnings were 642.00 million, an increase of 5.42%.
Financial numbers in DKK Financial StatementsNews
Ambu A/S Transcript: Q4 25/26
FY organic growth reached 10.1%, with Endoscopy Solutions up 16.4%; Q4 growth accelerated to 13.9%. FY 2026/27 guidance targets 9.5%-11.5% organic growth and a 13%-15% reported EBIT margin, alongside elevated launch investment.
Ambu A/S Quarterly report: Q4 2026
Ambu A/S has published its Q4 2026 quarterly earnings report on November 5, 2026.
Ambu A/S Annual report: Q4 2026
Ambu A/S has published its Q4 2026 annual report on November 5, 2026.
Ambu A/S Slides: Q4 2026
Ambu A/S has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on November 5, 2026.
Ambu A/S Transcript: Q3 25/26
Q3 saw 10.3% organic growth, led by 16% expansion in Endoscopy Solutions, now 64% of revenue. EBIT margin reached 13.5%, with full-year guidance at the upper end of 12%-14%. Strong cash flow and continued innovation support a positive outlook, despite FX and tariff headwinds.
Ambu A/S Quarterly report: Q3 2026
Ambu A/S has published its Q3 2026 quarterly earnings report on August 26, 2026.
Ambu A/S Slides: Q3 2026
Ambu A/S has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 26, 2026.
Ambu A/S Transcript: Q2 25/26
Endoscopy Solutions drove strong growth, offsetting A&PM declines, with guidance narrowed to 10%-12% revenue growth and EBIT margin maintained at 12%-14%. Share buyback expanded to DKK 450 million, and H2 is expected to see higher growth and margins.
Ambu A/S Quarterly report: Q2 2026
Ambu A/S has published its Q2 2026 quarterly earnings report on May 6, 2026.
Ambu A/S Slides: Q2 2026
Ambu A/S has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 6, 2026.
Ambu A/S Transcript: Q1 25/26
Q1 delivered 8.6% organic revenue growth, led by endoscopy (14.4%) and strong urology/respiratory momentum. EBIT margin was 10.5% (adjusted >15% excluding tariffs/FX), with full-year guidance maintained and tariff/FX headwinds expected to ease in H2.
Ambu A/S Quarterly report: Q1 2026
Ambu A/S has published its Q1 2026 quarterly earnings report on February 4, 2026.
Ambu A/S Slides: Q1 2026
Ambu A/S has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 4, 2026.
Ambu A/S Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong double-digit growth and a successful turnaround have positioned the company as a leader in single-use endoscopy, with a focus on respiratory and urology. Innovation, scalable operations, and a robust financial outlook support continued expansion, while competition and market conversion drive future growth.
Ambu A/S Slides: SEB Nordic Seminar presentation
Ambu A/S has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
ANNUAL REPORT 2022/23 (EARNINGS RELEASE)
For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high d...
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S...